BioStar Capital

What BioStar Capital does

BioStar Capital is a privately held venture capital partnership that invests in transformational medical device technologies, with a stated focus on cardiovascular and orthopaedic medicine. The firm is headquartered in Petoskey, Michigan, operates with a small team of 1–10 employees, and has been active in medtech investing for over two decades according to its own positioning. BioStar describes its competitive positioning as a "unique collaboration of renowned healthcare clinicians and executives, medical thought leaders, and financial professionals," combining domain clinical expertise with traditional venture investing.

The firm does not develop products itself; rather, it backs portfolio companies such as Amplitude Vascular Systems (AVS), which developed the Pulse IVL platform (also referred to as the Pulse System) — a next-generation hydraulic intravascular lithotripsy system that uses CO2-generated pressure waves delivered through a balloon catheter as an alternative to electric wired balloons and lasers for treating calcified peripheral arterial disease. In May 2026, AVS was acquired by Stryker for up to $835 million, representing a pre-FDA exit and a significant realization event for BioStar. BioStar also cites prior portfolio exits to Siemens Healthineers, Johnson & Johnson, and Medtronic as evidence of its track record.

As a venture capital GP, BioStar's revenue model is management fees on committed fund capital plus carried interest from portfolio company exits; specific AUM, fund size, vintage details, and revenue figures are not publicly disclosed. The firm distributes its investment activity through its website, LinkedIn presence, and press releases tied to portfolio milestones, and serves two principal customer segments: medical technology startups seeking capital and strategic guidance, and limited partners / fund investors seeking medtech exposure.

Name

BioStar Capital

Legal name

BioStar Capital

Website

https://www.biostar.capital

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

BioStar Capital is a privately held US venture capital partnership that invests in transformational medical device technologies focused on cardiovascular and orthopaedic medicine, serving medtech startups with growth capital and limited partners seeking medtech exposure.

Ownership category

akta.pro rank

Product category

Venture Capital / Healthcare Investment Management

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Medical technology venture capital
• Medtech growth investing
• Healthcare innovation funding
• Cardiovascular device investing
• Orthopaedic medtech investments

Headquarters

HQ city

Petoskey

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Marketing channels3 records

Core offering

BioStar Capital is a venture capital partnership that invests growth capital into transformational medical technology companies, with a focus on cardiovascular and orthopaedic medical devices. The firm raises capital from limited partners and deploys it into portfolio companies while providing clinical, strategic, and operational guidance drawn from its network of healthcare clinicians and medtech executives. Returns are generated through successful portfolio exits, with a track record of acquisitions by major healthcare strategics including Stryker, Siemens Healthineers, Johnson & Johnson, and Medtronic.

Product overview

BioStar Capital is a venture capital firm specializing in transformational medical technology investments, not a product company with its own product suite. Their portfolio includes Amplitude Vascular Systems (AVS), which developed the Pulse IVL platform (also known as the Pulse System) - a next-generation hydraulic intravascular lithotripsy system for treating calcified peripheral arterial disease. AVS was acquired by Stryker in May 2026 for $835 million. BioStar Capital's portfolio strategy has also produced prior exits to Siemens Healthineers, Johnson & Johnson, and Medtronic.

Differentiator

Problem solved

Functional benefit

Products and services

• Medtech Venture Capital Funds Venture capital funds managed by BioStar Capital that invest in transformational medical technology companies, primarily in cardiovascular and orthopaedic medicine. The funds provide growth capital to portfolio companies along with clinical, strategic, and operational guidance, targeting returns through eventual exits via acquisition by strategic healthcare buyers. Available to institutional limited partners and high-net-worth investors.
• Value-Add Portfolio Support Value-add investment services provided to BioStar Capital portfolio companies, combining business acumen with clinical expertise drawn from a network of healthcare clinicians, medical device executives, and medical thought leaders. This offering differentiates BioStar from generalist medtech VCs by providing portfolio companies with hands-on clinical, strategic, and operational guidance to accelerate development and prepare for strategic exit.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves4 records

Expansion highlights3 records

Broad incumbents

• RA Capital Management: Healthcare-focused investment manager with crossover and venture activity across biotech and medtech. Overlaps BioStar's healthcare investment universe but operates across a wider stage and modality range.
• New Enterprise Associates (NEA): Large multi-stage venture capital firm with a substantial healthcare practice covering medical devices and digital health. Overlaps with BioStar in medtech investing but at much broader scale and stage range.

Direct peers

• Apple Tree Partners: Healthcare-focused venture capital firm that partners with entrepreneurs to build medical device, biotech, and healthcare services companies. Similar clinical-plus-business value-add model to BioStar.
• Deerfield Management: Healthcare investment firm covering public and private medtech and life sciences companies. Comparable given specialized healthcare mandate and scale of medtech deal flow.
• InnovaHealth Partners: Medical device-focused private equity firm investing in growth-stage cardiovascular, orthopaedic, and other therapeutic device companies. Directly comparable category focus and exit profile.
• Versant Ventures: Healthcare-dedicated venture capital firm investing across medical devices, biopharma, and diagnostics. Highly comparable to BioStar given its focused healthcare thesis and stage-flexible approach to medtech investments.
• OrbiMed: Healthcare-focused investment firm with broad coverage across medtech, biotech, and healthcare services. Comparable to BioStar as a specialist healthcare VC with deep operating bench and a track record of exits to strategic acquirers.
• Aperture Venture Partners: Early-stage medtech-focused venture firm investing in interventional and surgical device technologies. Highly comparable niche focus on cardiovascular and orthopaedic-style device categories.

Regional players

• Sectoral Asset Management: Healthcare-focused investment manager with strong roots in Canadian and European markets. Comparable medtech focus but operates primarily outside the US, providing a regional contrast to BioStar's US-centric strategy.

Emerging players

• HealthTech Capital: Early-stage venture firm investing in healthcare technology and medical device companies. Smaller and earlier-stage than BioStar but shares a thematic focus on transformative medtech innovations.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/biostar-capital

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments49 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioStar Capital